Alonso-Fernández [10] | 2006 | OSA Control | >10 <5 | 31 15 | 43.6±23.6 4±3.3 | 53±13 48±10 | 30.4±4 28.7±4.7 | Baseline data of prospective study | 30/1 15/0 | 25.0±6.8 25.3±7.6 |
Beitler [24] | 2014 | OSA Control | >15 <15 | 15 19 | 37.6 (26.8–55.3)# 1.5 (0.7–5.4)# | 47.9±11.5 34.3±12.0 | 32.2±7.8 28.8±6.5 | Cross-sectional
| 12/3 10/9 | 19.1±6.4 25.2±9.5 |
Butner [32] | 2013 | Control Moderate OSA | <5 5–14.9 | 43 27 | 2.8±1.6 8.7±2.7 | 26±9 30±13 | 28±6 30±7 | Cross-sectional | 37/6 23/4 | 29.4±7.7 26.6±6.3 |
Cavagnolli [25] | 2014 | OSA Control | >5 <5 | 10 10 | 25.7±5.4 3.5±0.5 | 32.2±10.2 40.5±10.4 | 27.5±1.9 26.0±3.4 | Baseline data of prospective study | 10/0 10/0 | 39.7±7.6 39.3±7.0 |
Cepeda [63] | 2015 | MetS + OSA MetS – OSA | ≥15 <15 | 30 30 | 42±4 7±1 | 49±1.7 46±1.4 | 32±1 32±1 | Cross-sectional | 18/12 14/16 | 22.6±1.0 23.6±1.3 |
Chien [27] | 2012 | Severe OSA Control | >30 | 30 30 | 48.4±17.3 2.7±1.3 | 50.5±5.7 49.9±6.8 | 26.5±2.4 25.9±2.6 | Baseline data of prospective study | 30/0 30/0 | 25.0±3.97 27.7±2.8 |
Chien [26] | 2013 | OSA Control | >30 <5 | 11 11 | 46.2±22.6 2.7±1.1 | 50.3±5.1 50.6±5.7 | 26.6±3.6 26.4±3.5 | Between-group comparison | 11/0 11/0 | 24.5±3.4 28.1±2.9 |
Hargens [11] | 2008 | OSA Control | >5 <5 | 14 16 | 22.7±18.5 2.5±1.3 | 22.4±2.8 21.4±2.6 | 32.0±3.7 31.4±3.7 | Between-group comparison | 14/0 16/0 | 27.1±4.5 28.0±5.8 |
Innocenti [64] | 2012 | Morbidly obese + OSA Morbidly obese control | >5 <5 | 8 7 | 51.1±24.1 3.2±1.1 | 44±10.5 34.8 ±10.6 | 44.9±7.5 44.0±9.6 | Cross-sectional | 4/4 4/3 | 17.7±7.3 19.5±5.1 |
Kaleth [12] | 2007 | OSA Control − OSA | ≥5 <5 | 23 9 | 24.7±13.5 2.5±1.6 | 45.6±10.7 40.2±8.1 | 33.1±5.5 29.5±5.5 | Between-group comparison | 15/8 2/7 | 21.9±0.8 21.9±1.6 |
Kline [65] | 2013 | OSA Control | ≥15 <5 | 43 9 | 29.3±4.1 4.7±0.9 | 46.9±1.2 46.5±2.9 | 34.8±0.9 32.5±1.2 | Ancillary study to RCT | 24/19 5/4 | 21.6±0.8 22.1±2.3 |
Lin [13] | 2006 | OSA Control | RDI >30 RDI <10 | 20 20 | 44.0±8.2¶ 5.1±1.6¶ | 47±7 44±7 | 28.3±2.6 27.6±2.7 | Between-group comparison | 18/2 18/2 | 21.6±3.3 30.1±3.4 |
Nanas [28] | 2010 | OSA Control | ≥25 | 21 10 | 55±13
| 48±11 46±11 | 29.3±2.2 28.1±1.4 | Between-group comparison | 21/0 10/0 | 28.7±4.0 34.7±6.2 |
Ozturk [30] | 2005 | OSA Control | >5
| 19 11 | 46±19 | 46.9±8.6 40.6±8.4 | 30.7±4.6 28.9±3.0 | Between-group comparison | 16/3 7/4 | 19.8±3.1 21.8±5.9 |
Rizzi [29] | 2010 | Lean, sedentary OSA patients Controls | ≥5 <5 | 27 27 | 15.4±9.2 3.1±1.1 | 52.9±7.9 52.8±8.1 | 23.1±1.6 22.7±1.7 | Between-group comparison | 10/17 10/17 | 28.4±10.0 28.6±8.1 |
Rizzi [60] | 2013 | Lean OSA Lean control Obese OSA Obese control | AHI≥5 AHI<5 AHI≥5 AHI<5 | 22 36 31 26 | 22.4±11.2 2.8±1.3 33.3±22.9 2.9±1.5 | 53.7±8.1 50.8±6.4 50.7±6.4 49.1±7.6 | 22.1±1.6 22.8±1.6 33.6±2.9 33.4±2.6 | Between-group comparison | 10/12 9/27 7/24 5/21 | 32.1±9.5 30.5±7.4 21.7±6.3 24.7±7.5 |
Tryfon [31] | 2004 | OSA Control | >5 <5 | 17 10 | 33.3±22.4 N/A | 35 (22–45)# 35 (28–54)# | 34.7±7.6 32.5±4.3 | Between-group comparison | 17/0 6/4 | 24.6±7.2 23.1±5.9 |
Vanhecke [34] | 2008 | Morbidly obese + OSA Morbidly obese − OSA | AHI>15 or AHI>5 with ESS>10 | 42 50 | 32.5±26.6 2.5±2.3 | 46.2±11.0 45.0±8.7 | 50.5±9.4 47.2±9.1 | Between-group comparison | 13/29 15/35 | 17.6 ±4.2 21.1±3.8 |
Vanuxem [16] | 1997 | OSA Control | >10 | 11 9 | 25.6±1.2 | 47.8±4.1 41.9±3.1 | 26.6±1.0 26.4±1.2 | Between-group comparison | N/A | 26.4±1.2 33.2±1.4 |